Evidence map›Paper›PMID 25901316›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

NK cells require IL-28R for optimal in vivo activity.

Fernando Souza-Fonseca-Guimaraes, Arabella Young, Deepak Mittal, Ludovic Martinet, Claudia Bruedigam, Kazuyoshi Takeda, Christopher E Andoniou, Mariapia A Degli-Esposti, Geoffrey R Hill, Mark J Smyth

Expression of concernOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 100 citations in OpenAlex.

  1. Review
  2. Article
  3. Interferon Lambda: The Next Frontier in Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Fernando Souza-Fonseca-GuimaraesImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, St. Lucia, QLD 4006, Australia;
Arabella YoungImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, St. Lucia, QLD 4006, Australia;
Deepak MittalImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia;
Ludovic MartinetImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia;
Claudia BruedigamTranslational Leukaemia Research Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia;
Kazuyoshi TakedaDivision of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan;
Christopher E AndoniouImmunology and Virology Program, Centre for Ophthalmology and Visual Science, University of Western Australia, Crawley, WA 6009, Australia; Centre for Experimental Immunology, Lions Eye Institute, Nedlands, WA 6009, Australia;
Mariapia A Degli-EspostiImmunology and Virology Program, Centre for Ophthalmology and Visual Science, University of Western Australia, Crawley, WA 6009, Australia; Centre for Experimental Immunology, Lions Eye Institute, Nedlands, WA 6009, Australia;
Geoffrey R HillBone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; and Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Brisbane, QLD 4006, Australia.
Mark J SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, St. Lucia, QLD 4006, Australia; mark.smyth@qimrberghofer.edu.au.
QIMR Berghofer Medical Research Institute · AUJuntendo University · JPLions Eye Institute · AURoyal Brisbane and Women's Hospital · AUUniversity of Queensland · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are naturally circulating innate lymphoid cells that protect against tumor initiation and metastasis and contribute to immunopathology during inflammation. The signals that prime NK cells are not completely understood, and, although the importance of IFN type I is well recognized, the role of type III IFN is comparatively very poorly studied. IL-28R-deficient mice were resistant to LPS and cecal ligation puncture-induced septic shock, and hallmark cytokines in these disease models were dysregulated in the absence of IL-28R. IL-28R-deficient mice were more sensitive to experimental tumor metastasis and carcinogen-induced tumor formation than WT mice, and additional blockade of interferon alpha/beta receptor 1 (IFNAR1), but not IFN-γ, further enhanced metastasis and tumor development. IL-28R-deficient mice were also more susceptible to growth of the NK cell-sensitive lymphoma, RMAs. Specific loss of IL-28R in NK cells transferred into lymphocyte-deficient mice resulted in reduced LPS-induced IFN-γ levels and enhanced tumor metastasis. Therefore, by using IL-28R-deficient mice, which are unable to signal type III IFN-λ, we demonstrate for the first time, to our knowledge, the ability of IFN-λ to directly regulate NK cell effector functions in vivo, alone and in the context of IFN-αβ.

Indexed as

AnimalsCarcinogensCell SeparationCytokinesEndotoxinsFlow CytometryGene DeletionGene Expression RegulationInterferon Type IKiller Cells, NaturalLipopolysaccharidesMaleMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutCarcinogensCytokinesEndotoxinsInterferon Type Iinterleukin 28alpha receptorLipopolysaccharidesReceptors, CytokineRNA, Messengeranti-tumorIL-28RinterferonLPSNK cells

Identifiers

PMID25901316
PMCPMC4426428
OpenAlexW1989937401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.